3-(2-methoxyphenyl)-8-azabicyclo[3.2.1]octan-3-ol | 1185040-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(2-methoxyphenyl)-8-azabicyclo[3.2.1]octan-3-ol
• CAS: 1185040-04-3
• 化学式: C₁₄H₁₉NO₂
• mdl: MFCD05237193
• 分子量: 233.31
• InChiKey: OSNWWHCHTLEKOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-methoxyphenyl)-8-azabicyclo[3.2.1]octan-3-ol 、 (2S)-2-((tosyloxy)methyl)-8-methoxy-1,4-benzodioxane 生成 8-{[(2S)-8-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}-3-(2-methoxyphenyl)-8-azabicyclo[3.2.1]octan-3-ol
  参考文献：
  名称：

  8-AZA-bicyclo[3.2.1]octan-3-OL derivative of 2,3-dihydro-1,4-benzodioxan as 5-HT 1A antagonists

  摘要：

  公式为1的化合物可用于治疗因衰老、中风、头部创伤、阿尔茨海默病或其他神经退行性疾病、精神分裂症引起的认知缺陷，以及过度血清素刺激相关的疾病，如焦虑、攻击和压力，并用于控制各种生理现象，如食欲、体温调节、睡眠和性行为，这些生理现象已知至少在某种程度上受到血清素影响。

  公开号：

  US20040063728A1

文献信息

• 8-Aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benodioxan as 5-HT1A antagonists
  申请人：Wyeth

  公开号：US20030032648A1

  公开（公告）日：2003-02-13

  Compounds of the formula: 1 are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and also treatment of disorders related to excessive serotonergic stimulation, such as anxiety, aggression and stress, and for the control of various physiological phenomena, such as appetite, thermoregulation, sleep and sexual behavior, which are known to be, at least in part, under serotonergic influence.

  公式为1的化合物对治疗由于老化、中风、头部创伤、阿尔茨海默病或其他神经退行性疾病、精神分裂症引起的认知缺陷非常有用，同时也可用于治疗与过度5-羟色胺刺激有关的紊乱，如焦虑、攻击性和压力，以及控制各种生理现象，如食欲、体温调节、睡眠和性行为，这些现象至少部分受5-羟色胺影响。
• [EN] 8-AZA-BICYCLO[3.2.1]OCTAN-3-OL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN AS 5-HT1A ANTAGONISTS<br/>[FR] DERIVES DE 8-AZA-BICYCLO[3.2.1]OCTAN-3-OL DE 2,3-DIHYDRO-1,4-BENZODIOXAN UTILISES COMME ANTAGONISTES 5-HT1A
  申请人：WYETH CORP

  公开号：WO2002085900A1

  公开（公告）日：2002-10-31

  Compounds of the formula (I) are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and also treatment of disorders related to excessive serotonergic stimulation, such as anxiety, aggression and stress, and for the control of various physiological phenomena, such as appetite, thermoregulation, sleep and sexual behavior, which are known the be, at least in part, under serotonergic influence.

  公式（I）的化合物对于治疗由于衰老、中风、头部创伤、阿尔茨海默病或其他神经退行性疾病、精神分裂症所引起的认知缺陷以及与过度5-羟色胺刺激有关的紊乱，如焦虑、攻击和压力，以及控制各种生理现象，如食欲、体温调节、睡眠和性行为，这些现象至少部分受到5-羟色胺影响，具有治疗作用。
• 8-aza-bicyclo&lsqb;3.2.1&rsqb;octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan as 5-HT1A antagonists
  申请人：Wyeth

  公开号：US06656951B2

  公开（公告）日：2003-12-02

  Compounds of the formula: are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and also treatment of disorders related to excessive serotonergic stimulation, such as anxiety, aggression and stress, and for the control of various physiological phenomena, such as appetite, thermoregulation, sleep and sexual behavior, which are known to be, at least in part, under serotonergic influence.

  公式为：的化合物对于治疗由于衰老、中风、头部创伤、阿尔茨海默病或其他神经退行性疾病、精神分裂症所致的认知障碍以及与过度血清素刺激有关的疾病，如焦虑、攻击性和压力等障碍，以及控制各种生理现象，如食欲、体温调节、睡眠和性行为，这些现象至少部分受到血清素影响是有效的。
• (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use
  申请人：Webster Scott Peter

  公开号：US20120172393A1

  公开（公告）日：2012-07-05

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些(4-苯基哌啶-1-基)-[5-(1H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟化类固醇脱氢酶1型(11β-HSD1)的化合物。本发明还涉及包含此类化合物的制药组合物的使用，以及在体外和体内使用此类化合物和组合物以抑制11β-羟化类固醇脱氢酶1型；治疗由抑制11β-羟化类固醇脱氢酶1型改善的疾病；治疗代谢综合征，包括2型糖尿病和肥胖症等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢异常和心血管疾病，如缺血性(冠状)心脏病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。
• Photoreactive ligands and uses thereof
  申请人：The Scripps Research Institute

  公开号：US11535597B2

  公开（公告）日：2022-12-27

  Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.

  本文公开了用于确定蛋白质作为与小分子配体相互作用的靶标的方法。本文还公开了用于分析可药用蛋白质的小分子配体和组合物。